Lifestyle tops drugs (again) in delaying dementia

André Picard, The Globe and Mail

Another promising drug treatment for Alzheimer’s disease has tanked. Scientists and analysts alike had high hopes for solanezumab. There were predictions that it would be a blockbuster that could rack up sales of $10-billion a year. After all, in laboratory tests, the drug was able to bind to a protein called amyloid beta that builds up in the brain of Alzheimer’s patients. Theoretically, if you can keep the protein from clumping together to form a sticky plaque that clogs up the brain you should be able to stop the disease from progressing. But, in the real world, it didn’t work.

Read the rest here: